Modern Approach to Resistant Acromegaly

Overview

Journal Endocrine

Specialty Endocrinology

Date 2023 Feb 15

PMID 36790521

Authors

Andrea Giustina

Luigi Di Filippo

Melin M Uygur

Stefano Frara

Affiliations

Soon will be listed here.

Abstract

Background: Targets of acromegaly treatment are normalization of biochemical values, removal/reduction/stabilization of the pituitary mass, control of clinical activity and mortality with a multimodal/multidisciplinary approach. Despite significant technological and pharmacological progress, still several patients with acromegaly bear a resistant somatotroph adenoma and active disease may persist for many years with resultant poor clinical outcomes.

Aim: To review briefly definition and pathophysiology of resistance to acromegaly treatment and the options of medical treatment in this context, exploring the role of novel clinical and molecular biomarkers in the personalization of therapy and proposing updates to the currently available guidelines for the treatment of resistant GH-secreting adenomas.

Conclusions: In the last few years, in parallel with the increased number of medical options available for the therapy of acromegaly, relevant advances occurred in the understanding of the role of novel molecular and clinical biomarkers in predicting the responsiveness to second-line medical treatments, such as Pegvisomant and Pasireotide LAR, and helping clinicians in the personalization of the follow-up and treatment of resistant somatotroph adenomas. The integration of these findings into the existing guidelines may represent a possibly important step forward in the management of "difficult" acromegaly patients.

Citing Articles

Long-term clinical outcome of 103 patients with acromegaly after pituitary surgery.

Pennlund A, Esposito D, Bontell T, Skoglund T, Hallen T, Caren H Pituitary. 2025; 28(2):33.

PMID: 39987353 PMC: 11846723. DOI: 10.1007/s11102-025-01503-6.

Assessment of sarcopenic obesity in patients with acromegaly.

Rocha C, Hupalowski N, Andrade V, Boguszewski C, Borba V Pituitary. 2025; 28(1):25.

PMID: 39900878 DOI: 10.1007/s11102-024-01494-w.

IGF-I levels during standard Lanreotide dose predicts biochemical outcome of high-frequency regimen in acromegaly.

Chiloiro S, Giampietro A, Giambo P, Costanza F, Mattogno P, Lauretti L Pituitary. 2024; 28(1):7.

PMID: 39724447 DOI: 10.1007/s11102-024-01479-9.

Predictors of biochemical remission after transsphenoidal surgery in a large cohort of acromegaly patients.

Balagurunath K, Chrenek R, Gerstl J, Corrales C, Laws E, Mekary R Pituitary. 2024; 28(1):2.

PMID: 39708072 DOI: 10.1007/s11102-024-01472-2.

Novel approach to bone comorbidity in resistant acromegaly.

Frara S, Acanfora M, Franzese V, Brandi M, Losa M, Giustina A Pituitary. 2024; 27(6):813-823.

PMID: 39570564 DOI: 10.1007/s11102-024-01468-y.

References

Melmed S, Kaiser U, Lopes M, Bertherat J, Syro L, Raverot G . Clinical Biology of the Pituitary Adenoma. Endocr Rev. 2022; 43(6):1003-1037. PMC: 9695123. DOI: 10.1210/endrev/bnac010. View

Giustina A . Acromegaly and Vertebral Fractures: Facts and Questions. Trends Endocrinol Metab. 2020; 31(4):274-275. DOI: 10.1016/j.tem.2020.01.011. View

Giustina A, Boni E, Romanelli G, Grassi V, GIUSTINA G . Cardiopulmonary performance during exercise in acromegaly, and the effects of acute suppression of growth hormone hypersecretion with octreotide. Am J Cardiol. 1995; 75(15):1042-7. DOI: 10.1016/s0002-9149(99)80721-8. View

Mazziotti G, Gola M, Bianchi A, Porcelli T, Giampietro A, Cimino V . Influence of diabetes mellitus on vertebral fractures in men with acromegaly. Endocrine. 2011; 40(1):102-8. DOI: 10.1007/s12020-011-9486-x. View

Giustina A, Barkan A, Beckers A, Biermasz N, Biller B, Boguszewski C . A Consensus on the Diagnosis and Treatment of Acromegaly Comorbidities: An Update. J Clin Endocrinol Metab. 2019; 105(4). DOI: 10.1210/clinem/dgz096. View

Chiloiro S, Giampietro A, Gagliardi I, Bondanelli M, Veleno M, Ambrosio M . Impact of the diagnostic delay of acromegaly on bone health: data from a real life and long term follow-up experience. Pituitary. 2022; 25(6):831-841. PMC: 9362053. DOI: 10.1007/s11102-022-01266-4. View

Giustina A, Barkhoudarian G, Beckers A, Ben-Shlomo A, Biermasz N, Biller B . Multidisciplinary management of acromegaly: A consensus. Rev Endocr Metab Disord. 2020; 21(4):667-678. PMC: 7942783. DOI: 10.1007/s11154-020-09588-z. View

Frara S, Rodriguez-Carnero G, Formenti A, Martinez-Olmos M, Giustina A, Casanueva F . Pituitary Tumors Centers of Excellence. Endocrinol Metab Clin North Am. 2020; 49(3):553-564. DOI: 10.1016/j.ecl.2020.05.010. View

Casanueva F, Barkan A, Buchfelder M, Klibanski A, Laws E, Loeffler J . Criteria for the definition of Pituitary Tumor Centers of Excellence (PTCOE): A Pituitary Society Statement. Pituitary. 2017; 20(5):489-498. PMC: 5606938. DOI: 10.1007/s11102-017-0838-2. View

10.

Mortini P, Nocera G, Roncelli F, Losa M, Formenti A, Giustina A . The optimal numerosity of the referral population of pituitary tumors centers of excellence (PTCOE): A surgical perspective. Rev Endocr Metab Disord. 2020; 21(4):527-536. DOI: 10.1007/s11154-020-09564-7. View

11.

Amato G, Mazziotti G, Rotondi M, Iorio S, Doga M, Sorvillo F . Long-term effects of lanreotide SR and octreotide LAR on tumour shrinkage and GH hypersecretion in patients with previously untreated acromegaly. Clin Endocrinol (Oxf). 2002; 56(1):65-71. DOI: 10.1046/j.0300-0664.2001.01438.x. View

12.

Giustina A, Mazziotti G, Torri V, Spinello M, Floriani I, Melmed S . Meta-analysis on the effects of octreotide on tumor mass in acromegaly. PLoS One. 2012; 7(5):e36411. PMC: 3344864. DOI: 10.1371/journal.pone.0036411. View

13.

Mazziotti G, Giustina A . Effects of lanreotide SR and Autogel on tumor mass in patients with acromegaly: a systematic review. Pituitary. 2009; 13(1):60-7. DOI: 10.1007/s11102-009-0169-z. View

14.

Gola M, Bonadonna S, Mazziotti G, Amato G, Giustina A . Resistance to somatostatin analogs in acromegaly: an evolving concept?. J Endocrinol Invest. 2006; 29(1):86-93. DOI: 10.1007/BF03349183. View

15.

Giustina A, Chanson P, Bronstein M, Klibanski A, Lamberts S, Casanueva F . A consensus on criteria for cure of acromegaly. J Clin Endocrinol Metab. 2010; 95(7):3141-8. DOI: 10.1210/jc.2009-2670. View

16.

Giustina A, Bronstein M, Chanson P, Petersenn S, Casanueva F, Sert C . International Multicenter Validation Study of the SAGIT® Instrument in Acromegaly. J Clin Endocrinol Metab. 2021; 106(12):3555-3568. DOI: 10.1210/clinem/dgab536. View

17.

Giustina A, Bronstein M, Chanson P, Petersenn S, Casanueva F, Sert C . Staging and managing patients with acromegaly in clinical practice: baseline data from the SAGIT® validation study. Pituitary. 2019; 22(5):476-487. PMC: 6728296. DOI: 10.1007/s11102-019-00977-5. View

18.

Berton A, Prencipe N, Bertero L, Baldi M, Bima C, Corsico M . Resistance to Somatostatin Analogs in Italian Acromegaly Patients: The MISS Study. J Clin Med. 2023; 12(1). PMC: 9821091. DOI: 10.3390/jcm12010025. View

19.

Kontogeorgos G, Markussis V, Thodou E, Kyrodimou E, Choreftaki T, Nomikos P . Association of Pathology Markers with Somatostatin Analogue Responsiveness in Acromegaly. Int J Endocrinol. 2022; 2022:8660470. PMC: 9529452. DOI: 10.1155/2022/8660470. View

20.

Fusco A, Zatelli M, Bianchi A, Cimino V, Tilaro L, Veltri F . Prognostic significance of the Ki-67 labeling index in growth hormone-secreting pituitary adenomas. J Clin Endocrinol Metab. 2008; 93(7):2746-50. DOI: 10.1210/jc.2008-0126. View